Search clinical trials for: AZD8701

Total 38 results

AstraZeneca
Parexel; Spandauer Damm 130; 14050; Berlin, Germany

Completed

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Male Subjects With Type II Diabetes (T2DM)

Germany
AstraZeneca

Completed

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

United Kingdom
AstraZeneca

Completed

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

Healthy

United Kingdom
AstraZeneca

Completed

AZD8601 Study in CABG Patients

Heart Failure

Finland, Netherlands, Germany
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Completed

Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931

Healthy

United Kingdom
AstraZeneca

Terminated

Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Active, not recruiting

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Melanoma | Cervical Cancer | Small Cell Lung Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Non-Small-Cell Lung Cancer | Gastroesophageal Cancer | Clear Cell Renal Cell Cancer | Squamous Cell Cancer of Head and Neck

United States, Spain, Canada, France
AstraZeneca

Terminated

AZD8075 Single Ascending Dose Study

Healthy Volunteers

Sweden
AstraZeneca

Completed

Study of AZD8931 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Russian Federation, Germany
AstraZeneca

Completed

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

Healthy

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

Pain

United Kingdom
AstraZeneca

Withdrawn

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

Healthy
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
AstraZeneca

Recruiting

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Spain, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, China, Japan, Taiwan, Thailand, Hungary, Poland, Netherlands
AstraZeneca

Completed

A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Healthy

Sweden
AstraZeneca
Parexel

Completed

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

Chronic Obstructive Pulmonary Disease COPD

Germany, United Kingdom
AstraZeneca
Parexel

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel; Covance; The Doctors Laboratory; Industrias Farmacéuticas Almirall S.A.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Chronic Obstructive Pulmonary Disease - COPD

United Kingdom
AstraZeneca
Parexel

Not yet recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
AstraZeneca

Completed

AZD8108 SAD/MAD in Healthy Volunteers (AZD8108)

Healthy Volunteers

United States
Imperial College London
AstraZeneca; Medical Research Council; National Institute for Health Research...

Completed

Neuropeptide Treatment for Hot Flushes During the Menopause (NK3R)

Menopausal Flushing

United Kingdom
AstraZeneca

Terminated

Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment (CHIVE)

Breast Neoplasm

Korea, Republic of, Germany, Taiwan
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
AstraZeneca
Parexel

Completed

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
AstraZeneca

Completed

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

Neoplasms | Breast Cancer | Metastatic Cancer

Japan
AstraZeneca

Completed

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) (THYME)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Bulgaria, Czech Republic, Peru, Spain, United Kingdom, Sweden, Hungary, Belgium, Canada, Italy, France, Panama, Switzerland
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
AstraZeneca

Terminated

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Korea, Republic of, Spain, Taiwan, Germany, Japan
AstraZeneca

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

Spain, China, Korea, Republic of, United States, Taiwan, Japan, United Kingdom
AstraZeneca

Terminated

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (MINT)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Czech Republic, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, United Kingdom, Philippines, Ukraine, Finland, Canada, Taiwan, India, Thailand, United States, Japan
University College, London
AstraZeneca; Cancer Research UK; National Institute for Health Research, United...

Completed

Phase I/II Trial of Antagonism of HER in GI Cancer (PANTHER)

Metastatic Colorectal Cancer | Recurrent Colorectal Cancer

United Kingdom
UNICANCER
AstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC

Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)

Non-small Cell Lung Cancer Metastatic

France
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, Taiwan, Hong Kong, Switzerland, Poland, Japan
AstraZeneca

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Gastric Cancer | Pancreatic Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Spain, United Kingdom, Korea, Republic of, Japan, Taiwan, Malaysia, Canada, Singapore, Moldova, Republic of, Australia, Georgia
Pablo Tebas
AstraZeneca; Inovio Pharmaceuticals; The Wistar Institute

Recruiting

dMAbs for Prevention of COVID-19

Healthy Volunteers

United States
UNICANCER
AstraZeneca; Fondation ARC

Active, not recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

Metastatic Breast Cancer

France

Search clinical trials for: AZD8701

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations